Johnson & Johnson Reported Mixed Third-Quarter Results
The company posted $25.4 billion in revenue for the third quarter of 2026.
Updated on Oct. 13, 2026 in Economic Indicators
Live Poll
Do you trust that large public companies provide accurate and reliable financial outlooks to investors?
Johnson & Johnson reported $210 million in profit for the third quarter of 2026, with revenue reaching $25.4 billion. The company earned 9 cents per share, while adjusted earnings reached $2.59 per share.
Why it matters
The company's adjusted earnings exceeded analyst expectations, though overall revenue fell slightly short of projections. These figures provide insight into the financial health of the pharmaceutical giant and its performance heading into the end of the year.
Johnson & Johnson reported $25.4 billion in revenue, missing the $25.44 billion analyst estimate. The company projects full-year revenue between $101 billion and $101.4 billion.
The players
Johnson & Johnson
This multinational corporation is a leading provider of pharmaceuticals, medical devices, and consumer health products headquartered in New Brunswick, New Jersey.
The details
The healthcare firm based in New Brunswick, New Jersey, earned 9 cents per share for the quarter. Looking ahead, the company issued full-year earnings guidance between $11.05 and $11.15 per share.
Timeline
Johnson & Johnson reported Q3 2026 earnings on October 13, 2026.
Market Landscape
This earnings report aligns with the ongoing 2026 third-quarter earnings season, where corporations navigate fluctuating market expectations. The results reflect how the company balances current output against broader institutional forecasts for the fiscal year.
The firm's financial stability remains a key indicator for healthcare investors and those tracking broader pharmaceutical market trends. Consumers may monitor if these earnings projections correlate with future shifts in pricing or product availability for the company's health offerings.
The takeaway
Investors should weigh the company's adjusted earnings success against its slight revenue miss to gauge future performance. Tracking full-year projections provides a clearer picture of the firm's trajectory through the end of 2026.
Further reading
For broader trends in corporate performance, visit United States Economic Indicators.
More information
View the full details in the Zacks stock report on JNJ.
Live Poll
Do you trust that large public companies provide accurate and reliable financial outlooks to investors?
